Business Context and Reporting Period
This Form 8-K reports on the annual meeting of stockholders for Gemphire Therapeutics Inc. held on May 23, 2017. The report was filed on May 24, 2017. Note: The request metadata referenced "Metavia Inc.," but the filing text explicitly identifies the registrant as Gemphire Therapeutics Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding corporate governance events and does not contain financial statements.
Material Changes and Voting Results
The primary material event was the outcome of the annual stockholder meeting:
- Election of Directors: Two Class I directors were elected to three-year terms ending in 2020.
- Dr. Charles Bisgaier: 5,393,133 votes For; 215,726 votes Withheld; 1,662,511 Broker Non-Votes.
- Kenneth Kousky: 5,393,133 votes For; 215,726 votes Withheld; 1,662,511 Broker Non-Votes.
- Ratification of Auditors: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2017.
- Votes For: 7,187,297
- Votes Against: 52,394
- Votes Abstain: 31,679
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Investor Verification Checklist
- Verify the identity of the registrant (Gemphire Therapeutics Inc.) against the request metadata (Metavia Inc.).
- Confirm the tenure of the newly elected directors (Dr. Charles Bisgaier and Kenneth Kousky) through the 2020 annual meeting.
- Review the definitive proxy statement filed on April 6, 2017, for detailed background on the director nominees and auditor ratification.
- Note the significant number of Broker Non-Votes (1,662,511) regarding the election of directors.